FDA Approved: KRAZATI — Supplemental Application (Mirati Therapeutics, Inc)

View source ↗

Summary

The FDA approved a supplemental application for KRAZATI (adagrasib) submitted by Mirati Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KRAZATI (adagrasib)

Snippet

SUPPL AP for KRAZATI (ADAGRASIB)